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Objective: We hypothesize that airflow limitation is associated with increasing arterial stiff-
ness and that having COPD increases a non-invasive measure of arterial stiffness e the aortic
augmentation index (AIx) e independently of other CVD risk factors.
Methods: This population study is based on 3374 subjects from the Copenhagen City Heart
Study; 494 had COPD. We used multiple linear regression analyses to examine the association
between COPD and AIx adjusted for CVD risk factors. Furthermore, we analyzed the associa-
tion between AIx and FEV1, FVC and FEV1/FVC in the entire population.
Results: AIx was higher in subjects with COPD than in subjects without: 25.7 vs. 21.0
(p < 0.001) in men and 33.6 vs. 29.4 (p < 0.001) in women. We found no increase in AIx with
COPD adjusted for CVD risk factors: difference 0.63 (0.26 to 1.52, p Z 0.16). In sensitivity
analyses in subjects younger than 60 years with exclusion of mild COPD from the analyses,
COPD was associated with an increase in AIx in men only of 4.1 (0.88e7.22, p Z 0.007). AIx
had a curvilinear association with FEV1 and FVC but no association with the FEV1/FVC ratio.
Conclusion: AIx and COPD are only weakly associated. In the general population, this finding
argues against increased arterial stiffness, as measured by AIx, being a complication of COPD.
ª 2011 Elsevier Ltd. All rights reserved.of Cardiology and Respiratory Medicine 253, Hvidovre University Hospital, Kettega˚rd Alle´ 30, DK-2650
65; fax: þ45 3632 3755.
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398 J.H. Janner et al.Introduction Following written informed consent the participantsThere is considerable evidence that chronic obstructive
pulmonary disease (COPD) and cardiovascular disease (CVD)
coexist1 and it has been suggested that an increased risk of
CVD is a direct consequence of COPD.2 CVD is also a major
cause of mortality in patients with COPD.3,4 COPD and CVD
have common risk factors such as increased age, smoking,
and low socioeconomic status. Reduced forced expiratory
volume in 1 s (FEV1) is predictive of cardiovascular
mortality.5 However, after adjusting for established CVD
risk factors and other potential confounders this association
is weakened.6 As such, the mechanisms underlying the
association between CVD and COPD remain incompletely
understood.7,8
One proposed mechanism linking COPD and CVD is
increased arterial stiffness.2 Systemic inflammation is
present in COPD9 and accelerates and stimulates the
remodelling process with degradation of elastic fibres in the
arterial wall and replacement by collagen.10 This will lead
to increased arterial stiffness with increased afterload,
decreased perfusion of the coronary arteries and risk of
CVD.11 Aortic arterial stiffness can be measured non-
invasively by measuring pulse wave velocity (PWV) that is
a regional measurement of arterial stiffness. The aortic
Augmentation Index (AIx) is a measure of pulse wave
reflections, which is an alternative, more indirect global
measure of arterial stiffness12 that is dependent upon PWV
but also on height, heart rate, endothelial dysfunction and
changes in peripheral vascular smooth muscle cell
tone.11,12 AIx and PWV cannot be used interchangeably and
AIx may have some advantages since it is easier to measure
and some studies indicate that AIx is modifiable in
comparison to PWV.13,14
PWV has consistently been associated with COPD in two
COPD case-control studies,15,16 and has been associated
with FEV1 in European men in the general population
17,18
while three case-control studies have examined AIx in
relation to FEV1 or COPD, and have produced contradictory
findings.15,16,19
The association between AIx, COPD and FEV1 has not
previously been analyzed in a general population. There-
fore, we hypothesized that airflow limitation is associated
with increased arterial stiffness measured by AIx and that
having COPD increases AIx independently of other CVD risk
factors. We aimed at testing this hypothesis in a large
sample of the general population.
Methods
This cross-sectional study is based on data from The
Copenhagen City Heart Study, an ongoing epidemiological
survey started in 1976 complying with the Declaration of
Helsinki and approved by the Local Ethics Committee of
Copenhagen. The fourth survey took place between
September 2001 and July 2003 and 12,600 subjects e
randomly selected from the general population in Copen-
hagen were invited. The overall response rate was 50%,
which resulted in the examination of 6237 subjects (2660
men and 3577 women) between the ages of 20 and 97
years.20completed a questionnaire on lifestyle, previous diseases,
symptoms, medication and education. A physical exami-
nation was performed including assessments of blood
pressure measured in the left upper arm after 5 min of rest
using a London School of Hygiene sphygmomanometer,
spirometry and pulse wave analysis (PWA). A non-fasting
venous blood sample was analyzed for plasma levels of
glucose, high-sensitive C-reactive protein (HsCRP), total
cholesterol, high-density lipoprotein (HDL), low-density
lipoprotein (LDL) and triglycerides. Log-transformations of
HsCRP and triglycerides were made. Education was used as
a marker of socioeconomic status and was defined as short
if subjects had 3 years of education after secondary
school and was otherwise defined as long. Smoking status
was defined as never-smokers, ex-smokers or current
smokers. Physical activity was defined as more than 4 h of
physical activity (brisk walking, biking or exercise that
makes you breathless) per week.
Pre-bronchodilator FEV1 and forced vital capacity (FVC)
were measured using a Vitalograph Spirometer (Maids
Morton, UK) which was calibrated daily. Three sets of
values with two measurements differing by less than 5%
were obtained and only pre-bronchodilator values are
available. The highest measurements of FEV1 and FVC were
used in the analyses as absolute values and as percentages
of predicted values using internally derived reference
values based on a sub-sample of healthy never-smokers.21
COPD was defined as FEV1/FVC less than 70%, age more
than 40 years and no self-reported asthma.
Radial artery pulse waves were recorded non-invasively
by applanation tonometry of the radial artery using a high-
fidelity micromanometer (SPT-301B Miller Instruments,
Houston, Texas). Twenty waves were captured and pulse
wave analysis (SphygmoCor, West Ryde, Australia) was used
to derive a central aortic pulse wave and haemodynamic
measures by a generalized validated mathematical transfer
function.22e24 The pulse wave ascends through the aorta it
is reflected when it meets arteries with higher impedance.
In young healthy people the reflected wave reaches the
central aorta in the diastole. When arterial stiffness
increases the reflected wave tends to reach aorta in the
late systole augmenting the systolic pressure resulting in
increased left ventricular afterload and decreased perfu-
sion of the coronary arteries in the diastole. The AIx is
defined as the augmented pressure (AP) divided by the
pulse pressure (PP) (Fig. 1).25 PWA was measured in
a seated position after 5 min of rest. Pulse wave velocity
was not measured in the Copenhagen City Heart Study.
AIx was measured in 4561 subjects but not all of them
had equal numbers of measurements; some had several (up
to five) measurements taken during the one visit to the
clinic. AIx measurements in 1129 subjects were excluded
because of unacceptable quality according to a quality
score based on pulse height, pulse height variation, dia-
stolic variation, and contour of the pulse wave, which have
been published previously.25 If subjects had two or more
measurements of good quality the mean of these were used
in the analyses. The remaining 3374 subjects with good
quality of AIx and with no missing data on spirometry were
included in the study. Of these subjects 246 men and 248
women had COPD.
Figure 1 Pulse wave analyses and the derived measures.
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Two-sample t-test, two-sample test of proportions and
ANOVA was used to examine differences in subjects with or
without AIx measurements for analysis, to analyze differ-
ence in AIx between subjects with and without COPD and to
test for differences in AIx with COPD severity according to
GOLD. Multiple linear regression analyses of AIx on COPD
were initially adjusted for gender, age, age2, heart rate,
height and weight (partly adjusted model) and additionally
adjusted for systolic blood pressure, diastolic blood pres-
sure, total cholesterol, log-hsCRP, smoking status, physical
activity, and higher education (fully adjusted model). We
did sensitivity analyses in order to explore an association
between a more certain epidemiological diagnosis of COPD
and AIx; in these, regression models were stratified by
gender and repeated after excluding subjects with mild
COPD (GOLD I), and subjects aged over 60 years of age. In
total 270 subjects had missing data on CVD risk factors and
were excluded from the multiple regression analyses. Allmultiple regression analyses were weighted by a covariate
indicating quality and how many measurements were used
to calculate means of AIx. To estimate the weights gener-
alized least squares method were used.
Generalized additive models (GAM) with loess smoothing
functions were used to explore and visualize the association
between AIx and FEV1, AIx and FVC and AIx and the ratio
FEV1/FVC as well as the other covariates and to test for
deviation from linearity.26 The GAM analyses were per-
formed with R 2.6.2 (R Foundation, Vienna, Austria). All
other analyses were performed using STATA 10 (STATA SE
10.0 for windows, Collage Station, TX, USA). Two-tailed p-
values with p < 0.05 were considered statistically
significant.Results
Characteristics of the cohort with good quality AIx
measurements are presented in Table 1. Missing values of
400 J.H. Janner et al.AIx were equally distributed in subjects with COPD (204 of
848) and in the rest of the population (1472 of 5389)
(p Z 0.07), and there was no difference in potential
confounders included in the regression models or in the
distribution of GOLD stages between COPD groups with and
without missing data of AIx (data not shown).
We found significantly higher unadjusted values of AIx in
subjects with COPD than subjects without COPD in both
genders: 25.7 vs. 21.0 (p < 0.001) in men and 33.6 vs. 29.4
(p < 0.001) in women. However, AIx did not differ according
to COPD severity using GOLD staging as shown in Table 2. In
a crude regression model COPD was associated with
a significantly higher AIx (3.63, 95% confidence interval
2.41e4.85 (p < 0.001)). COPD was still significantly asso-
ciated with a higher AIx (1.33, 0.41e2.26 (p Z 0.005)) in
the partly adjusted model. When the analysis was repeated
in a model fully adjusted for CVD risk factors the associa-
tion between AIx and COPD was no longer statistically
significant (pZ 0.16) as shown in Table 3. The key CVD risk
factor, which changed the association between AIx and
COPD, was smoking status as seen in the Supplement Table.
In sensitivity analyses excluding subjects with mild COPD
and subjects older than 60 years we found that moderate to
severe COPD was associated with an increase in AIx of 4.1,
0.88e7.22 (p Z 0.007) corresponding to approximately 6
years of ageing. However, in women we found no associa-
tion between moderate to severe COPD and increase in AIx
(0.37, 3.73 to 4.48 (p Z 0.86)).
Next, we used the generalized additive model (GAM)
on AIx as a function of FEV1 or FVC as well as FEV1/FVC in
the whole population and found a similar and significant
but non-linear association between FEV1 and AIx in bothTable 1 Characteristics of the 3374 subjects with good quality
results are presented as mean  SD or numbers (%).
Variable All (n Z 3374)
Age, (years) 58.7  16.2
Gender, (men) 1473 (43.7)
Heart rate (bpm) 68.3  10.8
Height, (cm) 169.5  9.7
Weight, (kg) 74.7  14.5
Systolic BP, (mmHg) 138.8  22.8
Diastolic BP, (mmHg) 79.1  11.8
Cholesterol, (mM) 5.5  1.2
HsCRP, (mg/L) 3.3  6.8
AIx (%) 26.4  12.8
FEV1, (L/s) 2.7  0.9
FVC, (L) 3.5  1.1
Smoking status
Ex-smokers 1150 (34.6)
Current-smokers 1082 (32.5)
Short education 2199 (65.6)
Physical activity
> 4 h weekly 1379 (41.0)
COPD
GOLD I 180 (5.3)
GOLD II 261 (7.7)
GOLD III 48 (1.4)
GOLD IV 5 (0.1)genders (p Z 0.001) adjusted for age and other CVD risk
factors as shown in Fig. 2. AIx had a linear increase with
decreasing FEV1 when FEV1 was normal or supra normal,
but when FEV1 was less than approximately 3 L the AIx
levelled off and reached a plateau. Multiple linear
regression analyses were subsequently used as a para-
metric model to obtain estimates, p-values and confi-
dence intervals for FEV1; results of these analyses are
shown in Table 4.
We found similar associations between AIx and FVC (data
not shown); however, there did not seem to be any asso-
ciation at all between FEV1/FVC and AIx neither using the
GAM procedure (data not shown), nor in the multiple
regression analyses (p Z 0.37 for men and p Z 1.00 for
women).Discussion
This study showed a significant association between COPD
and arterial stiffness measured by AIx after controlling for
confounders but only in men younger than 60 years of age
when mild COPD were excluded. This association was not
significant in young women, it was not significant in the
elderly and we found no doseeresponse relationship
between AIx and spirometric severity of COPD. Although AIx
increased with both decreasing FEV1 and decreasing FVC,
there was no relationship between AIx and FEV1/FVC. We
observed a significant curvilinear association between AIx
and FEV1 in both men and women, with AIx reaching
a plateau when FEV1 was 3 L or less. A similar association
was seen between FVC and AIx.of AIx measurements and no missing data of spirometry. The
< 60 years (n Z 1541)  60 years (n Z 1833)
44.1  10.8 70.9  7.5
710 (46.1) 763 (41.6)
67.8  10.9 68.8  10.8
173.0  9.2 166.6  9.0
75.4  14.6 74.1  14.3
126.6  17.9 149.1  21.3
77.2  11.8 80.7  11.5
5.2  1.2 5.7  1.1
2.1  3.7 4.3  8.3
20.6  13.1 31.3  10.2
3.3  0.8 2.2  0.7
4.2  1.0 2.9  0.9
435 (28.7) 715 (39.5)
516 (34.0) 566 (31.3)
734 (48.1) 1465 (80.2)
725 (47.2) 654 (35.8)
48 (3.1) 132 (7.2)
56 (3.6) 205 (11.2)
6 (0.4) 42 (2.3)
1 (0.1) 4 (0.2)
Table 2 AIx in subjects divided into categories of COPD severity according to GOLD classification.
GOLD I GOLD II GOLD III GOLD IV p-value
AIx e Men 26.0  13.4 26.3  11.3 24.3  10.5 21.6  9.6 0.76
AIx e Women 33.2  9.4 33.8  9.8 35.1  9.7 e 0.66
The difference in AIx in GOLD categories is analyzed using ANOVA. There were no female subjects with COPD GOLD IV.
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in our study and was only found in younger men with
moderate and severe disease. There were a number of
reasons for doing the sensitivity analyses. In our study COPD
was defined by the pre-bronchodilator FEV1/FVC ratio and
by this definition it is possible that subjects with mild
airway obstruction but not COPD are included in GOLD I and
this could dilute the association between COPD and AIx.
Subjects older than 60 years were excluded based on
previous studies questioning the use of AIx as a measure-
ment of arterial stiffness in the elderly27e29 and the anal-
yses where stratified by gender because of the well known
higher AIx in women compared to men.30
Previous studies examining AIx in COPD have been
equivocal. Two small case-control studies have reported
that AIx is increased in COPD,15,16 although one of them
only included men.16 In a larger but still modest sample
there was no association, although augmentation pressure
(AP) was higher in COPD patients in this study.19 Some
residual confounding might exist in these studies, since
patients with COPD were not selected on similar criteria in
the study by Sabit and co-workers15; in fact, the COPD
patients had higher systolic blood pressure, higher heart
rate and a higher proportion were current smokers e all
factors known to be strongly associated with AIx.31Table 3 The association between COPD and AIx adjusted for C
Co
COPD (yes vs. no)
Gender (men) 
Age (years)
Age2 (years)
Men 
Women 
Heart rate (bpm) 
Height (cm) 
Weight (kg) 
Systolic BP (mmHg)
Diastolic BP (mmHg)
Cholesterol (mM)
Log-hsCRP (mg/L)
Ex-smoker 
Current smoker
Education (long) 
Physical activity (>4 h weekly) 
R2Z 0.53. *p < 0.05; **p < 0.01; ***p < 0.001. There were 3104 subjec
and age
2
was found (p < 0.001). COPDZ chronic obstructive pulmona
was defined as short if subjects had  3 years of education after seco
was defined as more than 4 h of physical activity (brisk walking, bikinFurthermore, adjusting for smoking status in our study
had a crucial influence on the association between AIx and
COPD and it is possible that associations found in previous
studies could be the result of residual confounding from
smoking. In the study by Mills and co-workers absence of
CVD was an inclusion criterion for controls. The reliance on
case-control studies in COPD for looking at cardiovascular
co-morbidity can be questioned because of the difficulty of
dealing with unmeasured confounding from well-
established cardiovascular risk such as socioeconomic
status in a case-control design.
In the remaining studies on COPD and arterial stiffness,
PWV was used as a measure of arterial stiffness. PWV was
higher in COPD patients and increased with COPD
severity15,16 and McAllister and co-workers found a signifi-
cant correlation between carotid-radial PWV and emphy-
sema in patients with COPD.32 It can be argued against the
use of carotid-radial PWV as a measure of arterial stiffness
since brachial arteries contains less elastin fibres than aorta
and therefore is less susceptible to the elastin collagen
remodelling.11
We found a significant association between FEV1, FVC
and AIx and to our knowledge we are the first to report this
association in a large general population. In addition we
add to previous studies in documenting an associationVD risk factors using multiple regression analyses.
efficient 95% CI
0.63 (0.26 to 1.52)
7.01*** (8.59 to 5.42)
0.96*** (0.83e1.09)
0.006*** (0.007 to 0.005)
0.007*** (0.008 to 0.006)
0.39*** (0.42 to 0.36)
0.24*** (0.29 to 0.18)
0.09*** (0.12 to 0.06)
0.07*** (0.05e0.09)
0.12*** (0.08e0.15)
0.32* (0.05e0.59)
0.42*** (0.12e0.72)
0.18 (0.93 to 0.57)
2.40*** (1.61e3.19)
1.21*** (1.91 to 0.51)
0.85*** (1.48 to 0.22)
ts included in the analysis. Significant interaction between gender
ry disease. HsCRPZ high-sensitive C-reactive protein. Education
ndary school and was otherwise defined as long. Physical activity
g or exercise that makes you breathless) per week.
Figure 2 The association between AIx and FEV1 in men and women using the Generalized Additive Models (GAM) procedure.
402 J.H. Janner et al.between arterial stiffness and lung function in women.
Previous population studies have shown association
between lung function and PWV in European men17,18 while
another study including 678 adult Japanese Americans
found no association.33 Sabit and co-workers reported
a relationship between AIx and FEV1 in their rather healthy
control group with normal to supra-normal lung function,
but not in the patients with COPD. This supports our results
of a curvilinear association between FEV1 and AIx where
subjects without COPD contributed significantly to the
association seen.Our study is the largest to date to examine the associ-
ation between arterial stiffness, COPD, and lung function
and contributes to the limited amount of evidence in this
field. Based on the current knowledge it is difficult to make
any firm conclusions about arterial stiffness in COPD. One
mechanism for increased arterial stiffness in COPD patients
could be shared susceptibility to degradation of elastin in
different organs such as skin,34 lungs and arteries.2 Other
links could be systemic inflammation, since systemic
inflammation is present in COPD9 and accelerates and
stimulates the process with degradation of elastic fibres in
Table 4 The association between AIx and FEV1 in the entire population adjusted for CVD risk factors using multiple regression
analyses.
Men (n Z 1346) Women (n Z 1758)
Coefficient 95% CI Coefficient 95% CI
FEV1 (L/s) 3.25* (0.39e6.11) 4.45** (1.30e7.60)
FEV1
2 (L/s) 0.74*** (1.19 to 0.30) 1.18*** (1.85 to 0.52)
Age (years) 0.62*** (0.41e0.84) 0.90*** (0.72e1.08)
Age2 (years) 0.004*** (0.01 to 0.002) 0.006*** (0.01 to 0.004)
Heart rate (bpm) 0.38*** (0.42 to 0.34) 0.41*** (0.45 to 0.37)
Height (cm) 0.20*** (0.29 to 0.11) 0.17*** (0.25 to 0.10)
Weight (kg) 0.09*** (0.13 to 0.05) 0.09*** (0.13 to 0.05)
Systolic BP (mmHg) 0.10*** (0.06e0.13) 0.06*** (0.03e0.08)
Diastolic BP (mmHg) 0.11*** (0.06e0.16) 0.12*** (0.08e0.17)
Cholesterol (mM) 0.52** (0.13e0.92) 0.16 (0.20 to 0.53)
Log-hsCRP (mg/L) 0.51* (0.03e1.00) 0.24 (0.16 to 0.63)
Education (long) 1.15* (2.20 to 0.11) 1.01* (1.95 to 0.07)
Physical activity (>4 h weekly) 0.95 (1.92 to 0.02) 0.68 (1.52 to 0.16)
Ex-smoker 0.07 (1.29 to 1.15) 0.18 (1.14 to 0.77)
Current smoker 2.78*** (1.50e4.06) 1.96*** (0.95e2.97)
R2 (men)Z 0.48. R2 (women)Z 0.50. *p < 0.05; **p < 0.01; ***p < 0.001. FEV1 Z Forced expiratory volume in 1 s. FVCZ Forced vital
capacity. HsCRP Z high-sensitive C-reactive protein. Education was defined as short if subjects had 3 years of education after
secondary school and was otherwise defined as long. Physical activity was defined as more than 4 h of physical activity (brisk walking,
biking or exercise that makes you breathless) per week.
Arterial stiffness in COPD 403the arterial wall,10 or accelerated ageing, as age is an
important determinant of arterial stiffness and COPD.2,11,28
It has been argued that AIx is a suboptimal measure of
arterial stiffness in the elderly as AIx reaches a plateau with
age.25,28 Even though the arteries get stiffer and augmen-
tation pressure increases28 the pulse pressure increases
relatively more with age resulting in the plateau of AIx.35
This could explain the missing association between COPD
and AIx in the total population despite a possible increase
in arterial stiffness. Unfortunately PWV were not measured
in the Copenhagen City Heart Study so we were not able to
test the mentioned hypothesis.
Besides questioning the usefulness of AIx to measure
arterial stiffness the results of our study raise a critical view
to the association between arterial stiffness and COPD. We
found no independent association between arterial stiff-
ness and COPD after controlling for known confounders in
the total population, in women and in the elderly. AIx in
subjects with low lung function was similar to that of those
in the middle range, and AIx was only lower in subjects with
FEV1 > 3 L. Since FEV1 and FVC both had similar associa-
tions with AIx and we found no relationship between AIx
and FEV1/FVC in the entire population, the association
between FEV1 and AIx may be unrelated to airway
obstruction. Reduced FEV1 and FVC are independent
markers of cardiovascular events and mortality5 although
the exact mechanism behind this association is not clear.36
FEV1 can be a marker of general health or be an indicator of
environmental factors influencing perinatal growth or
growth in general,36,37 factors that could affect both the
lung and the vascular system negatively.
A limitation of this study is the cross-sectional design,
which implies that we cannot infer causal mechanism
between COPD and arterial stiffness. AIx should optimally
be coupled with PWV to give a more complete picture ofarterial stiffness12 and measurements of PWV in the
Copenhagen City Heart Study would have added important
knowledge on arterial stiffness in COPD.
In conclusion we found no independent association
between arterial stiffness and COPD after controlling for
known confounders in the total population, in women or in
the elderly indicating that arterial stiffness is not a conse-
quence of COPD. We cannot rule out that the explanation of
this finding is the inadequacy of AIx as a measure of arterial
stiffness in COPD. Further larger longitudinal studies where
both AIx and PWV should be measured are required to
provide insight into the association between arterial stiff-
ness and COPD.
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